Literature DB >> 11206268

Efficient tumor regression induced by genetically engineered tumor cells secreting interleukin-2 and membrane-expressing allogeneic MHC class I antigen.

S B Qian1, Y Li, G X Qian, S S Chen.   

Abstract

PURPOSE: To analyze the immunotherapeutic potentials of genetically engineered tumor cells secreting IL-2 and a membrane-expressing allogeneic MHC class I molecule Kb in a murine hepatoma model.
METHODS: In order to express both genes in coordination in the target cells, we constructed a polycistronic retroviral vector containing Kb, IL-2, and NeoR genes using two internal ribosome entry sites (IRES). Tumor growth was carried out by implantation of transduced tumor cells into mouse, while anti-tumor effects were demonstrated by the treatment of established tumors. The infiltrated cells were analyzed by immunohistochemistry.
RESULTS: The combined effect of IL-2 secretion and alloantigen expression on immunostimulation was demonstrated by the rejection of transduced tumor cells. In the treatment of established tumors, the Kb/IL-2 co-expressing tumor cells induced strong anti-tumor immunity, superior to that induced by the single gene-transduced cells. The increased diversity of infiltrated cell types in tumor sites indicated that both a specific and non-specific immune response had been activated.
CONCLUSION: Our study provides evidence that tumor cells with IL-2 secretion and membrane-expression of allogeneic MHC class I antigen are capable of inducing both strong tumor rejection and immunity.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11206268     DOI: 10.1007/s004320000176

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  2 in total

1.  Pharmacokinetics of radioimmunotherapeutic agent of direct labeling mAb 188Re-HAb18.

Authors:  Chao Lou; Zhi-Nan Chen; Hui-Jie Bian; Jie Li; Shou-Bo Zhou
Journal:  World J Gastroenterol       Date:  2002-02       Impact factor: 5.742

2.  Immune microenvironment in tumor progression: characteristics and challenges for therapy.

Authors:  Valerie Chew; Han Chong Toh; Jean-Pierre Abastado
Journal:  J Oncol       Date:  2012-08-08       Impact factor: 4.375

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.